Article

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat

University of California, San Francisco, San Francisco, California, United States
Breast Cancer Research and Treatment (Impact Factor: 3.94). 09/2007; 105(1):17-28. DOI: 10.1007/s10549-006-9430-6
Source: PubMed

ABSTRACT

Botanical therapies are often used by breast cancer patients yet few clinical trials have evaluated their safety and efficacy. We studied mechanisms of activity and performed a phase I clinical trial in patients with advanced breast cancer to evaluate BZL101, an aqueous extract from Scutellaria barbata.
Preclinical studies were conducted in vitro to characterize cell death induced by BZL101. In a phase I trial, eligible patients had histologically confirmed, measurable metastatic breast cancer. Treatment consisted of 350 ml per day of oral BZL101, administered as sole cancer therapy until disease progression, toxicity or personal preference to discontinue. Primary endpoints were safety, toxicity and tumor response.
BZL101 extract induced strong growth inhibition and apoptosis of breast cancer cell lines. In the phase I trial, 21 patients received BZL101. Mean age was 54 years (30-77) and mean number of prior treatments for metastatic disease was 3.9 (0-10). There were no grade III or IV adverse events (AEs). The most frequently reported BZL101-related grade I and II AEs included: nausea (38%), diarrhea (24%), headache (19%) flatulence (14%), vomiting (10%), constipation (10%), and fatigue (10%). Sixteen patients were evaluable for response. Four patients had stable disease (SD) for >90 days (25%) and 3/16 had SD for >180 days (19%). Five patients had objective tumor regression, one of which was 1 mm short of a PR based on RECIST criteria.
BZL 101 inhibits breast cancer cell lines by inducing apoptosis. In a phase I clinical trial, BZL101 was safe and had a favorable toxicity profile. BZL101 demonstrated encouraging clinical activity in this heavily pretreated population.

Download full-text

Full-text

Available from: Hope Rugo
  • Source
    • "Kral [4] reported the appearance of S. racemosa in the southeast U.S. Ethnobotanical information suggests that the Cauca people of Columbia and Ecuador used certain ecotypes of S. racemosa in ceremonial or sedative preparations [5]. S. barbata has been tested in two clinical trials for the treatment of advanced and metastatic breast cancer with positive results [6] [7]. Laboratory studies using Barbat skullcap extracts have shown to induce apoptosis in prostate cancer, and hepatoma H22 cells [8]-[10]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Micropropagation protocols to minimize hyperhydricity were optimized for medicinal Scutellaria barbata and Scutellaria racemosa. Six cytokinins and eight different carbon sources at two differ-ent incubation periods of 14 and 21 days were studied for adventitious shoot bud induction using nodal explants. In S. barbata, 5 µM meta-Topolin and 0.1 µM NAA supplemented shoot induction medium produced four shoots each after 14 and 21 day incubation. Observation of S. racemosa nodal explants recorded four and five shoots after 14 and 21 day incubation. In both species, con-trol explants (no plant growth regulators in the medium) consistently resulted in the bud break with two shoots in both 14 and 21 day incubation. The effect of carbon source on shoot regenera-tion was studied by supplementing eight different sugars at 0.1 M concentration to the optimized shoot induction medium (5 µM meta-Topolin and 0.1 µM NAA). S. barbata nodal explants cultured on shoot induction medium supplemented with fructose and glucose for 14 days produced 10 and nine adventitious shoots respectively; and after 21 day incubation adventitious shoot count reached 19 in glucose supplemented medium. S. racemosa explants in the same experiment pro-duced five shoots in maltose and four shoots in sorbitol supplemented medium after 14 day incu-bation; whereas after 21 day incubation, sucrose and maltose produced five shoots; fructose, glu-cose, and sorbitol produced four shoots. Regenerated plants were successfully acclimatized and Scanning Electron Microscopy of the leaf surface revealed differences in stomatal behavior and cuticle deposition between in vitro and acclimatized plants. The antioxidant assay conducted on both Scutellaria species showed considerable total polyphenol content, TEAC activity and flavo-noid content in fresh and dried leaf samples attributing to their medicinal potential.
    Full-text · Article · Nov 2014 · American Journal of Plant Sciences
  • Source
    • "Bezielle inhibits breast cancer cell lines by inducing apoptosis in vitro. In a phase I clinical trial in the USA, Bezielle was safe and had a favorable toxicity profile[30]. The result of an open-label, phase IB, multicenter trial demonstrated that oral administration of Bezielle was safe, well tolerated, and showed promising clinical evidence of anticancer activity in this heavily pretreated population of women with metastatic breast cancer[31]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Metastasis is the major cause of cancer-related deaths. Targeting the process of metastasis has been proposed as a strategy to fight cancer. Scutellaria barbata D. Don (S. barbata), a traditional Chinese medicine, is used for treatment of many diseases, including cancer. This study aimed to determine the anti-metastatic effect of total flavonoids of S. barbata (TF-SB) using the human hepatocarcinoma MHCC97H cell line with high metastatic potential. Our results show that TF-SB could significantly inhibit the proliferation and invasion of MHCC97H cells in a dose-dependent manner. MMP-2 and MMP-9 expression were obviously decreased after TF-SB treatment at both the mRNA and protein level. TIMP-1 and TIMP-2 expression were simultaneously increased. The present study indicates that TF-SB could reduce the metastatic capability of MHCC97H cell, probably through decrease of the MMP expression, and simultaneous increase of the TIMP expression.
    Full-text · Article · Jan 2013 · Molecules
  • Source
    • "Thus, strategies targeting AIF-mediated caspase-independent cell death have been applied as a therapeutic treatment for cancers. For example, a plant drug from Scutellaria barbatae that stimulates AIF translocation from the mitochondria to the nucleus showed anti-tumor effects in breast cancer patients [24]. Since cathepsin release from lysosomes regulates the AIF-mediated cell death pathway and several members of the cathepsin family have been implicated in cancer progression and metastasis [25], [26], cathepsin is a potential target to modulate caspase-independent cell death for cancer treatment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Berberine, an isoquinoline alkaloid derived from plants, is a traditional medicine for treating bacterial diarrhea and intestinal parasite infections. Although berberine has recently been shown to suppress growth of several tumor cell lines, information regarding the effect of berberine on colon tumor growth is limited. Here, we investigated the mechanisms underlying the effects of berberine on regulating the fate of colon tumor cells, specifically the mouse immorto-Min colonic epithelial (IMCE) cells carrying the Apc(min) mutation, and of normal colon epithelial cells, namely young adult mouse colonic epithelium (YAMC) cells. Berberine decreased colon tumor colony formation in agar, and induced cell death and LDH release in a time- and concentration-dependent manner in IMCE cells. In contrast, YAMC cells were not sensitive to berberine-induced cell death. Berberine did not stimulate caspase activation, and PARP cleavage and berberine-induced cell death were not affected by a caspase inhibitor in IMCE cells. Rather, berberine stimulated a caspase-independent cell death mediator, apoptosis-inducing factor (AIF) release from mitochondria and nuclear translocation in a ROS production-dependent manner. Amelioration of berberine-stimulated ROS production or suppression of AIF expression blocked berberine-induced cell death and LDH release in IMCE cells. Furthermore, two targets of ROS production in cells, cathepsin B release from lysosomes and PARP activation were induced by berberine. Blockage of either of these pathways decreased berberine-induced AIF activation and cell death in IMCE cells. Thus, berberine-stimulated ROS production leads to cathepsin B release and PARP activation-dependent AIF activation, resulting in caspase-independent cell death in colon tumor cells. Notably, normal colon epithelial cells are less susceptible to berberine-induced cell death, which suggests the specific inhibitory effects of berberine on colon tumor cell growth.
    Full-text · Article · May 2012 · PLoS ONE
Show more